Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755349 | 0.89 | PIK3CA (0.42) | AKT1AKT2PIK3CAMTOR | |
| SCHEMBL755747 | 0.84 | PARP1 (0.33) | AKT1AKT2PIK3CAMTOR | |
| SCHEMBL754345 | 0.77 | PIK3CA (0.45) | MAPK1RAB9ASMN1; SMN2PIK3CAMTOR | |
| SCHEMBL751843 | 0.72 | PIK3CA (0.43) | AKT1AKT2SMN1; SMN2PIK3CAMTOR | |
| SCHEMBL754305 | 0.67 | PIK3CA (0.60) | RAB9ASMN1; SMN2PIK3CAMTOR | |
| SCHEMBL22153369 | 0.67 | PDE10A (0.46) | AKT1AKT2ADORA3ADORA1RAB9A | |
| SCHEMBL7974764 | 0.66 | PI4KB (0.38) | AKT1AKT2ADORA3PDE10A | |
| SCHEMBL756821 | 0.66 | PIK3CA (0.47) | ADORA3ADORA1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL23414969 | 0.65 | METTL3 (0.45) | ADORA3ADORA1METTL3 | |
| SCHEMBL7977849 | 0.64 | PDE10A (0.39) | AKT1AKT2ADORA3ADORA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | AKT1 30/4885AKT2 38/4885ADORA3 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.